Seo Jung-jin Celltrion

South Korea's biopharmaceutical company Celltrion Inc. announced on Monday that it has signed a contract with the US biotech firm Rani Therapeutics ...

MILAN – South Korea's biopharmaceutical company Celltrion Inc. is known in Europe for its biosimilar products such as autoimmune disease treat...

South Korean biosimilar giant Celltrion Inc. revealed on Wednesday the highly anticipated clinical phase 1 data for its Actemra biosimilar, CT-P47, ...

More than 500 South Korean companies from top business groups to AI-based biotech startups are slated to attend the Bio International Convention 202...

Jin Air Co., a low-cost carrier (LCC) under Korean Air Co., is seeking to expand its air routes to Indonesia and Singapore this year with the additi...

South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Adminis...

South Korean biopharmaceutical company Celltrion Healthcare Co. revealed on Monday its introduction of Remsima SC, a treatment for autoimmune diseas...

South Korea’s largest hypermarket chain E-Mart Inc., a unit of a local retail giant Shinsegae Group, suffered a drop in its share prices to a ...

Celltrion Inc. announced on Tuesday it has decided not to pursue the acquisition of the biopharmaceutical unit of U.S. medical device maker Baxter I...

South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ...

NEW YORK – Sovereign wealth fund Korea Investment Corporation (KIC) is considering expanding alternative investments in Asian emerging markets...

South Korean biopharmaceutical company Celltrion Healthcare Co. on Thursday said it ranked in the top 10 out of 400 companies last year on the Turki...

Shinhan Financial Group's Chairman Jin Ok-dong is set to embark on his first overseas business trip since taking office as chairman last month. From...

Michael ByungJu Kim, co-founder and partner at private equity firm MBK Partners, has topped the ranking of the 50 richest South Koreans by net worth...

South Korea's Celltrion Healthcare Co. on Monday said it launched on the US market Vegzelma, a biosimilar of Bevacizumab, a medication for colorecta...

South Korean biosimilar giant Celltrion Group aims to transform into a drug developer by generating 40% of sales from new medicines by 2030 as it is...

South Korean biosimilar giant Celltrion Group’s founder Seo Jung-jin has returned to management two years after his departure, pledging to mer...

Celltrion Inc., South Korea’s largest biosimilar maker, said on Tuesday it has studied a possible acquisition of the biopharma solutions unit ...

South Korean biopharmaceutical firm Celltrion Inc. announced on Tuesday a joint research and development agreement with Genuv, Inc., a domestic drug...

South Korea’s biosimilar giant Celltrion Group’s founder and Honorary Chairman Seo Jung-jin is readying to return to management just two...

South Korea's biopharmaceutical company Celltrion Inc. will develop an anti-cancer drug that combines oncolytic virus technology with biosimilars un...

Celltrion Pharm Inc., a South Korean biopharmaceutical company, said on Monday it received certification from Brazil’s health regulator for it...

South Korean biopharmaceutical company Celltrion Inc. reported on Wednesday that its biosimilar drug Truxima (rituximab), a generic version of Roche...

South Korea's low-cost carriers (LCC) Jeju Air Co. and Jin Air in the fourth quarter last year each earned operating profit for the first time since...

Celltrion Healthcare Co. Ltd. said on Thursday that it launched Vegzelma, a biosimilar to the anti-cancer drug Avastin (active ingredient: bevacizum...

Celltrion Inc. has secured an additional stake in the UK's antibody-drug conjugate (ADC) developer Iksuda Therapeutics.According to Celltrion on Wed...

Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...

South Korea's Celltrion Healthcare Co. on Tuesday said that for the second straight year, it landed an order for infliximab, an antibody used to tre...

South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...

South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma...